Abstract
The link between cancer, hypertension and anti-hypertensive drug treatment is controversial. Despite numerous studies looking either directly or indirectly at cancer and hypertension, the results are often conflicting and do little to answer the dominant questions of cause and effect. Also, the treatment of hypertension has continued to evolve, with newer therapies being made available including angiotensin- converting enzyme inhibitors. Whilst the potential link with cancer is thought to be small at worst, with the overall benefits of hypertension faroutweighing its negative impacts, the suggestion of a carcinogenic role for either hypertension or its treatment continues to be an emotive issue, and needs firm answers. In this review, we provide an overview establishing the strengths and weaknesses of the arguments presented and highlight possible pharmacophysiological pathways involved.
Keywords: Hypertension, anti-hypertensive, cancer
Current Pharmaceutical Design
Title: Hypertension, Anti-Hypertensive Therapy and Neoplasia
Volume: 13 Issue: 25
Author(s): Patrick K.Y. Goon, Paul S. Stonelake and Gregory Y.H. Lip
Affiliation:
Keywords: Hypertension, anti-hypertensive, cancer
Abstract: The link between cancer, hypertension and anti-hypertensive drug treatment is controversial. Despite numerous studies looking either directly or indirectly at cancer and hypertension, the results are often conflicting and do little to answer the dominant questions of cause and effect. Also, the treatment of hypertension has continued to evolve, with newer therapies being made available including angiotensin- converting enzyme inhibitors. Whilst the potential link with cancer is thought to be small at worst, with the overall benefits of hypertension faroutweighing its negative impacts, the suggestion of a carcinogenic role for either hypertension or its treatment continues to be an emotive issue, and needs firm answers. In this review, we provide an overview establishing the strengths and weaknesses of the arguments presented and highlight possible pharmacophysiological pathways involved.
Export Options
About this article
Cite this article as:
Goon K.Y. Patrick, Stonelake S. Paul and Lip Y.H. Gregory, Hypertension, Anti-Hypertensive Therapy and Neoplasia, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663073
DOI https://dx.doi.org/10.2174/138161207781663073 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Markers in Older People at Risk of Mobility Limitations
Current Pharmaceutical Design Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design Triple Antiplatelet Therapy after PCI - Should or Could it be Done?
Cardiovascular & Hematological Disorders-Drug Targets Current and Future Treatment Options in Idiopathic Pulmonary Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Synthesis and Anxiolytic Activity of Some Novel 5-oxo-1, 4-oxazepine Derivatives
Letters in Drug Design & Discovery Chronopharmaceuticals: Hype or Future of Pharmaceutics
Current Pharmaceutical Design A Systematic Review of Drugs in Late-Stage Development for the Treatment of Multiple Sclerosis: A Focus on Oral Synthetic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Statins in Aortic Stenosis
Current Pharmaceutical Design Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Treatment of Allergic Rhinitis in Children
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Evaluation of Valsartan Biopharmaceutics Properties
Current Drug Research Reviews Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimers Disease
Current Neuropharmacology Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology